PHARMA SERVICES

SEE US AT STAND 40

Demand for Biotech packaging drives significant PCI investment at multiple locations world wide



PCI recognise that biologically derived therapeutic products are the new frontier, heralding revolutionary treatments of a number of diseases and injuries. We have committed to a $20m investment in support of biologic medicines and advanced injectable delivery forms. Expanding our Biotech clinical and commercial packaging and release testing capability at our Centre of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations to further support our existing Biotech infrastructure.

The pharmaceutical landscape continues to evolve with more and more products in development being deemed potent. As the biological activity and specificity of the API increases, dosage strengths decrease leading to an increased potency of the API itself in terms of the occupational handling for drug product manufacture.

With such specialised therapies and highly potent API comes a need for specialist handling with a move away from traditional personal protective equipment (PPE) towards technology based contained engineering solutions.

PCI is able to demonstrate a long and successful track record in the development and manufacture of potent products. Our award winning Centre of Excellence for contained development and manufacturing enables the safe development and clinical and commercial manufacture of products with an OEL as low as 0.01µg/m^3 (eight hour time weighted average). Our facility also offers contained roller compaction technology and a fully contained micro-dosing system providing automated drug-in-capsule (DIC) for early stage development delivering a faster route to clinic for our clients.

PCI's latest investment will include capacity expansion for cutting edge technologies for the labeling and assembly of state-of-the-art safety syringes, autoinjector and pen devices with integrated high speed cartoning, in-line serialisation, as well as furthering its expansive onsite Cold Chain storage.

PCI's injectable delivery form capabilities include ampoules, vials, cartridges and standard prefilled syringes, as well as advanced safety syringes, autoinjectors and pen devices with services including both simple and complex kitting for clinical and commercial applications.

In handling biologic medicines, we maintain a comprehensive Cold Chain and Ultra Cold Chain portfolio with temperature ranges from refrigerated 2-8°C, frozen -20°C, -40°C, -80°C and cryogenic temperatures of -196°C for Advanced Medicinal Therapeutic Products (ATMP), including cell and gene therapy medicines.

WEDNESDAY 19TH JUNE 11AM

Small Molecule Stream

David O'Connell, Director of Scientific Affairs, will share how potent APIs can be developed and manufactured into suitable drug dosage forms including; solid oral, non-sterile oral liquids and semi-solid creams and ointments whilst adhering to the highest quality standards.

Attendees will learn about the complexities at each stage of the development lifecycle, from the earliest phase of First in Man (FiM) studies, moving through ongoing clinical development and process optimisation of complex formulations, ultimately resulting in commercialisation and global supply.

CEO OF PCI PHARMA SERVICES

Salim Haffar

"I am pleased to share this news regarding our continued investment to support the needs of our biotech customers. It's estimated that close to 40 per cent of all medicines in pipeline development are biologic, and amazing new therapies are being developed and commercialised every day. With the development and commercialisation wave of biologic medicines, the market is rapidly evolving. We are proud to be the partner of choice for drug development companies as they look to outsource these specialised requirements for clinical and commercial packaging. These investments demonstrate our commitment to bring lifesaving medicines to patients around the world."

e : sales@pciservices.com w : pciservices.com